Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGC NASDAQ:NBTX NYSE:PRME NASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.80-4.3%$1.26$0.77▼$5.80$431.73M0.7630.23 million shs40.22 million shsNBTXNanobiotix$8.94-3.2%$6.65$2.76▼$10.59$428.85M0.4716,476 shs2,254 shsPRMEPrime Medicine$3.24-5.8%$3.69$1.11▼$5.17$436.02M2.392.53 million shs3.03 million shsSAVACassava Sciences$2.28-4.2%$2.18$1.15▼$33.98$110.14M-2.06720,491 shs386,165 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth0.00%+41.73%+71.43%+48.76%-65.45%NBTXNanobiotix0.00%-11.40%+32.74%+116.26%+49.00%PRMEPrime Medicine0.00%-8.73%-19.80%+172.27%-24.30%SAVACassava Sciences0.00%+3.64%+7.55%+7.04%-92.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth0.5793 of 5 stars0.02.00.00.03.20.81.3NBTXNanobiotix0.6685 of 5 stars1.33.00.00.03.30.00.6PRMEPrime Medicine2.5862 of 5 stars3.41.00.00.01.45.00.6SAVACassava Sciences2.0341 of 5 stars1.01.00.04.72.30.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.33SellN/AN/ANBTXNanobiotix 2.50Moderate Buy$8.00-10.51% DownsidePRMEPrime Medicine 2.75Moderate Buy$8.92175.21% UpsideSAVACassava Sciences 2.00Hold$2.00-12.28% DownsideCurrent Analyst Ratings BreakdownLatest SAVA, PRME, CGC, and NBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025CGCCanopy GrowthZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.007/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$225.65M1.91N/AN/A$1.90 per share0.95NBTXNanobiotix$39.18M10.94N/AN/A($1.51) per share-5.92PRMEPrime Medicine$4.96M87.89N/AN/A$1.37 per share2.36SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%11/14/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/ASAVACassava Sciences-$24.34M-$2.55N/AN/AN/AN/A-66.16%-53.11%11/13/2025 (Estimated)Latest SAVA, PRME, CGC, and NBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SAVACassava SciencesN/A-$0.18N/A-$0.92N/AN/A8/8/2025Q1 2026CGCCanopy Growth-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/APRMEPrime Medicine$1.4544.63%N/AN/A N/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.593.072.12NBTXNanobiotixN/A1.041.04PRMEPrime MedicineN/A6.506.50SAVACassava SciencesN/A2.432.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%NBTXNanobiotix38.81%PRMEPrime Medicine70.37%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth0.16%NBTXNanobiotix3.45%PRMEPrime Medicine22.74%SAVACassava Sciences12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150239.85 million239.47 millionOptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionablePRMEPrime Medicine234134.57 million100.38 millionOptionableSAVACassava Sciences3048.31 million42.41 millionOptionableSAVA, PRME, CGC, and NBTX HeadlinesRecent News About These CompaniesGMT Capital Corp Takes $675,000 Position in Cassava Sciences, Inc. $SAVASeptember 1 at 6:00 AM | marketbeat.comCassava Technologies Unveils AI Factory for Africa, Powered by NVIDIA SupercomputersAugust 25, 2025 | thezimbabwemail.comTCassava Sciences (NASDAQ:SAVA) Announces Quarterly Earnings ResultsAugust 18, 2025 | marketbeat.comCassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deCassava Sciences reports Q2 EPS (92c) vs 13c last yearAugust 14, 2025 | msn.comCassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerAugust 7, 2025 | globenewswire.comGinkgo Bioworks Holdings Q2 Earnings PreviewAugust 6, 2025 | msn.comCassava Sciences Announces Positive Preclinical ResultsAugust 6, 2025 | theglobeandmail.comCassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related EpilepsyAugust 4, 2025 | globenewswire.comSAVA - Cassava Sciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMCassava Sciences presents poster at TSC 2025 on SimufilamJune 30, 2025 | msn.comCassava Presents Promising Preclinical Simufilam Data at TSC Alliance MeetingJune 30, 2025 | globenewswire.comSAVA Stock Price for Cassava Sciences Inc - MorningstarJune 28, 2025 | morningstar.comMWhy cassava could be a great addition to a balanced dietJune 26, 2025 | msn.comCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava partners with Zindi to give African AI developers better toolsMay 15, 2025 | techzim.co.zwTCassava Sciences Inc.May 15, 2025 | barrons.com5 ON YOUR SIDE: Lead levels in cassava flourMay 15, 2025 | kstp.comKCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAVA, PRME, CGC, and NBTX Company DescriptionsCanopy Growth NASDAQ:CGC$1.80 -0.08 (-4.26%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.58 -0.22 (-12.44%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Nanobiotix NASDAQ:NBTX$9.28 +0.05 (+0.49%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Prime Medicine NYSE:PRME$3.24 -0.20 (-5.81%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.29 +0.05 (+1.54%) As of 08/29/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Cassava Sciences NASDAQ:SAVA$2.28 -0.10 (-4.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.27 -0.01 (-0.44%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
